Huan Jin

发表

Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp.

Huijun Sun, Xiaodong Ma, Q. Meng, 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

IFT20 confers paclitaxel resistance by triggering β-arrestin-1 to modulate ASK1 signaling in breast cancer.

Zhiming He, Ni Qiu, Hao-ming Xia, 2021, Molecular cancer research : MCR.

ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay

J. Chen, Haining Zhu, E. Kasarskis, 2018, Proceedings of the National Academy of Sciences.

Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.

J. Baselga, T. Wilson, N. Harbeck, 2018, Journal of Clinical Oncology.

A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).

L. Pusztai, J. Baselga, T. Wilson, 2016 .

Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐A

Jun Yu Li, C. Dinardo, K. Pratz, 2022, American journal of hematology.

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US

A. Gershon, M. Onishi, W. Donnellan, 2022, The oncologist.

Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy.

Ni Qiu, Hongsheng Li, Huan Jin, 2021, Life sciences.

Organic anion transporters and PI3K–AKT–mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein

Huijun Sun, Xiaodong Ma, Zhihao Liu, 2020, Journal of cellular physiology.

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.

J. Baselga, T. Wilson, J. Ware, 2017, Cancer discovery.

Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Sandra, J. Baselga, T. Wilson, 2017 .

Abstract OT1-03-14: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients withPIK3CA-mutant tumors

J. Baselga, T. Wilson, N. Harbeck, 2016 .

Identification and validation of a novel ferroptosis-related gene model for predicting the prognosis of gastric cancer patients

Jian-ying Ma, Gang Liu, Huan Jin, 2021, PloS one.

RWD-derived response in multiple myeloma

K. Yousefi, S. Tyanova, Shaji K. Kumar, 2023, PloS one.

Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

M. Konopleva, H. Kantarjian, C. Dinardo, 2020 .

Use of Venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) - Real World (RW) Response, Treatment Duration, Dose and Schedule Modifications

G. Ramsingh, W. Donnellan, Huan Jin, 2020 .

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.

J. Baselga, J. Ware, D. Juric, 2017, Cancer discovery.